Carbamazepine (Epilepsy)

Study	Exclusion reasons	Rmk	Reference
Wiggs (Carbamazepine), 2020	repeat population groups, duplicate reports (most recent study included)	EXCLUDED: Overlapping: Totally included in Madley-Dowd 2024. Children who were multiples were dropped. Crude data are not specified for monotherapy exposure.	Wiggs Neurology 2020; 95:e3232-e3240 10.1212/WNL.0000000000010993
He (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2017	repeat population groups, duplicate reports (most recent study included)	Patients who developed epilepsy during pregnancy or after delivery were not included. Overlapping: He 2017 totally included in Li 2023, with a longer study period and more pregnancies => Use of Li 2023.	He Epilepsy Behav 2017; 74:10-14 10.1016/j.yebeh.2017.05.034
He (Carbamazepine) (Controls unexposed, sick), 2017	repeat population groups, duplicate reports (most recent study included)	Patients who developed epilepsy during pregnancy or after delivery were not included. Overlapping: He 2017 totally included in Li 2023, with a longer study period and more pregnancies => Use of Li 2023.	He Epilepsy Behav 2017; 74:10-14 10.1016/j.yebeh.2017.05.034
Gopinath (Carbamazepine), 2015	repeat population groups, duplicate reports (most recent study included)	Overlapping: Thomas 2022 included data on language and cognitive delay, also evaluated in Sreedharan et al., 2018; Thomas 2007 and Gopinath 2015, but with more exposed pregnancies, more relevant control group and older children => Use of Thomas 2022.	Gopinath Epilepsy Res 2015; 117:58-62 10.1016/j.eplepsyres.2015.09.003
Thomas (Carbamazepine), 2007	repeat population groups, duplicate reports (most recent study included)	Overlapping: Thomas 2022 included data on language and cognitive delay, also evaluated in Sreedharan et al., 2018; Thomas 2007 and Gopinath 2015, but with more exposed pregnancies, more relevant control group and older children => Use of Thomas 2022.	Thomas Epilepsia 2007; 48:2234-40 10.1111/j.1528-1167.2007.01376.x